ArticleCancer research communications2026
Supermeres Containing the Discoidin Domain Receptor 1 Extracellular Domain Promote Collagen Alignment and Immune Exclusion in Microsatellite-Stable Colorectal Cancer.
Article in Cancer research communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
Abstract
Immune checkpoint blockade (ICB) is an effective treatment for microsatellite instability-high (MSI-H) colorectal cancers that are highly infiltrated by CD8+ T cells. Microsatellite-stable (MSS) colorectal cancers are unresponsive to ICB, at least in part, due to the paucity of intratumoral CD8+ T cells. We recently identified discoidin domain receptor 1 (DDR1) as one of four genes associated with CD8+ T-cell exclusion in MSS colorectal cancer. There are conflicting reports about the presence and role of the cleaved ectodomain (cECD) of DDR1 in mouse models of breast and pancreatic cancers. To explore the role of the DDR1 cECD in human colorectal cancer, we developed Collagen Alignment and Spatial Transcriptomics Analysis (CASTA), which revealed that genes involved in fibroblast contractility were associated with both DDR1 tumor expression and collagen alignment as determined by label-free second harmonic generation (2HG) imaging of the tumor collagen. Using 3D collagen cocultures of colorectal cancer spheroids and fibroblasts, we show that DDR1 promotes collagen alignment and CD8+ T-cell exclusion. We found large amounts of DDR1 cECD in MSS colorectal cancer supermeres, 25- to 35-nm secreted amembranous nanoparticles. Supermeres containing DDR1 cECD were sufficient to induce contraction of human colonic fibroblasts. We propose a model in which supermeres containing the DDR1 cECD promote the contraction of stromal fibroblasts in MSS colorectal cancer, leading to collagen alignment and CD8+ T-cell exclusion. These results support DDR1 cECD as an attractive therapeutic target in MSS colorectal cancer. SIGNIFICANCE: In human colorectal cancer, supermeres containing the DDR1 ectodomain promote fibroblast contraction and collagen alignment to exclude intratumoral CD8+ T cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.